Gilgamesh Advances Pipeline Of Novel Psychoactive Drugs Aimed At Revolutionizing Psychiatric Disorders Treatment
Private psychedelics biotech company Gilgamesh Pharmaceuticals is currently developing a diverse portfolio of novel, potentially first-in-class compounds targeting mechanisms with demonstrated clinical efficacy, onset duration or prolonged treatment duration, for the treatment of psychiatric conditions.
